Publications
Search our bibliography using the filters on the right-hand side.
Displaying 101 through 150 of 10229 publications.
Skip to main content
Abellan A, Burn E, Trinh NTH, Burkard T, Callahan A, Fernandez-Bertolin S, Hurley E, Rodriguez C, Segundo E, Morales DR, M E Nordeng H, Duarte-Salles T. Expanding the OMOP common data model to support perinatal research in network studies. Pharmacoepidemiol Drug Saf. 2025 Feb;34(2):e70106. doi: 10.1002/pds.70106
Barrett A, Olayinka-Amao O, Ziemssen T, Bharadia T, Henke C, Kamudoni P. A plain language summary of a study exploring the experiences of people with relapsing-remitting multiple sclerosis: what symptoms and impacts of the disease matter most and how can they be evaluated better? Neurodegener Dis Manag. 2025 Feb;15(1):9-16. doi: 10.1080/17582024.2024.2441068
Villa K, Vass C, Yarlas A, Ruggles J, Bordone L, Kent C, Mansfield C. Patient preferences for attributes of prophylactic treatment in hereditary angioedema: a discrete-choice experiment. Poster presented at the AAAIO/WAO Joint Conference; February 25, 2025. San Diego, CA. [abstract] J Allergy Clin Immunol. 2025 Feb; 155(2 Suppl):AB228. doi: 10.1016/j.jaci.2024.12.701
Patel JN, Chaihorsky L, Dong OM, Lu CY, Moretz C, Reese E, Teeple W, Brown B, Rogers S. Medical policy determinations for pharmacogenetic tests among US health plans. Am J Manag Care. 2025 Feb 1;31(2):e47-55. doi: 10.37765/ajmc.2025.89683
Glitza Oliva IC, Palaia J, Sakkal LA, Patel D, Moshyk A, Han N, Odak S, Schmier JK, Ning N, Chandra S. Real-world outcomes in patients with melanoma brain metastasis: a US multisite retrospective chart review study of systemic treatments. BMJ Open. 2025 Jan 30;15(1):e091098. doi: 10.1136/bmjopen-2024-091098
Fridman I, Smith C, Barrett A, Johnson S, Bhowmick A, Hayes S, Elston Lafata J. Navigating disagreements on health information: how patients with cancer perceive health care providers' approaches to discussing patient-identified information. JCO Oncol Pract. 2025 Jan 28. doi: 10.1200/OP.24.00071
Hellwig K, Magyari M, MacDonald TM, Cesta CE, Wergeland S, Leinonen MK, Ornoy A, Vukusic S, Lauer A, Zhou X, Kawai A, Weinrib R, Arana A, Boumenna T. A multi-country cohort database study to assess pregnancy and infant outcomes after potential maternal or paternal exposure to cladribine tablets in the treatment of multiple sclerosis: the CLEAR study methods and status update1. Ther Adv Neurol Disord. 2025 Jan 27;18:175628642. doi: 10.1177/17562864241310996
Blauvelt A, Reckleff J, Zhao Y, Clark M, Kosa K, Harris N, Esfandiari E, Martin S, Whalley D, Emma GY. Content evaluation of pruritus, skin pain, and sleep disturbance patient-reported outcome measures in adolescents and adults with moderate-to-severe atopic dermatitis: qualitative interviews. Br J Dermatol. 2025 Jan 24;192(2):247-60. doi: 10.1093/bjd/ljae346
Tripathee S, Treweek S, Van Hemelrijck M, Ross P, Watson V, MacLennan G, Guntupalli AM, Adams J, Majmudar B, Murchie P, Bekheit M, MacLennan SJ, ICANEQUAL Community of Expertise. ICANEQUAL multi-stakeholder partnership: reducing inequalities in liver cancer (HCC) diagnosis, treatment and care across the UK. NIHR open research. 2025 Jan 21;5:5. doi: 10.3310/nihropenres.13723.1
Dine J, Guan Y, Milien M, Ervin C, Byrne DD, Brown ML, De Anda C, Norquist JM. Evaluation of the content validity of the COVID-19 symptoms daily diary. Patient Relat Outcome Meas. 2025 Jan 17;16:37-53. doi: 10.2147/PROM.S488914
Wright GC, Zueger PM, Copley-Merriman K, Khan S, Costello J, Krumbach A, Reddy P, Tanjinatus O, Wells AF. Health disparities in rheumatology in the United States. Open Access Rheumatol. 2025 Jan 9;17:1-12. doi: 10.2147/OARRR.S493457
Romano (DeMuro) C, Bratlee-Whhitaker E, Hartry A, Mearns E, Taylor J, Taylor G, Callahan L, Monks D, Kremer I, Lappin D, Frangiosa T, Sangodkar S, Herring WL, Gnanasakthy K, Goss D, McLeod L, Edwards T, Poulos C, DiBenedetti D, Paulsen R. Measuring what matters most to people living with Alzheimer's disease and care partners: What Matters Most quantitative research development. Poster presented at the Alzheimer's Association International Conference (AAIC) 2024; July 31, 2024. Philadelphia, PA. [abstract] Alzheimers Dement. 2025 Jan 9; 20(S4):E085103. doi: 10.1002/alz.085103
Ahn JH, da Silva Pedrosa M, Lopez LR, Tibbs TN, Jeyachandran JN, Vignieri EE, Rothemich A, Cumming I, Irmscher AD, Haswell CJ, Zamboni WC, Yu YA, Ellermann M, Denson LA, Arthur JC. Intestinal E. coli-produced yersiniabactin promotes profibrotic macrophages in Crohn's disease. Cell Host Microbe. 2025 Jan 8;33(1):71-88.e9. doi: 10.1016/j.chom.2024.11.012
Smith A, Gore J, Chisolm S, Squires P, Li H, Franco S, Vass C, Liu X, Mansfield C. Muscle invasive bladder cancer treatment selection in an emerging treatment era: a patient preference study. Poster presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium; February 13, 2025. San Francisco, CA. [abstract] J Clin Oncol. 2025; 43(Suppl 5):753.
Chebib FT, Dahl N, Zhou X, Garbinsky D, Wang J, Nunna S, Oberdhan D, Fernandes AW. Tolvaptan and autosomal dominant polycystic kidney disease progression in individuals aged 18–35 years: a pooled database analysis. Kidney Med. 2025 Jan;7(1):100935. doi: 10.1016/j.xkme.2024.100935
Hill NL, Do J, Bratlee-Whitaker E, Turner JR, Sillner A, Fishman C, Mogle J. Views of aging and subjective cognition in middle-aged and older adults: a systematic review. Gerontology. 2025 Jan;71(1):49-70. doi: 10.1159/000542507
Ollendorf D, Tsiao E, Whittington M, Ronquest N. Role of economic evaluations in value assessments for pharmaceutical interventions in the United States. Presented at the ISPOR Education Center Online Learning; 2025.
Halsby K, Dobler G, Easton A, Karelis G, Krbkova L, Kyncl J, Sellner J, Strle F, Veje M, Zajkowska J, Zavadska D, Angulo FJ, Pilz A, Erber W, Gabriel M, Russo J, Price M, Madhava H, Meyding-Lamade UK. Evaluating the need for standardised disease manifestation categories in patients infected with the tick-borne encephalitis virus: a Delphi panel. Ticks Tick Borne Dis. 2025 Jan;16(1):102431. doi: 10.1016/j.ttbdis.2024.102431
Samuelsson K, Rivas I, Raimbault B, Dominguez A, Galmes T, Valentin A, Foraster M, Gascon M, Persavento C, Psyllidis A, Gomez Roig MD, Olive EL, Nieuwenhuijsen MJ, Helbich M, Sunyer J, Dadvand P. A comprehensive GPS-based analysis of activity spaces in early and late pregnancy using the ActMAP framework. Health Place. 2025 Jan;91:103413. doi: 10.1016/j.healthplace.2025.103413
La EM, Bunniran S, Garbinsky D, Reynolds M, Schwab P, Poston S, Harrington L. Respiratory syncytial virus knowledge, attitudes, and perceptions among adults in the United States. Hum Vaccin Immunother. 2024 Dec 31;20(1):2303796. doi: 10.1080/21645515.2024.2303796
La EM, Graham J, Singer D, Molnar D, Poston S, Curran D, Pickett J, Verelst F. Cost-effectiveness of the adjuvanted RSVPreF3 vaccine among adults aged ≥60 years in the United States. Hum Vaccin Immunother. 2024 Dec 31;20(1):2432745. doi: 10.1080/21645515.2024.2432745
Perdrizet J, Wilson M, Wannaadisai W, Apodaca K, Grant L. Pneumococcal serotypes missing prespecified efficacy threshold in immunogenicity trials: real-world evidence from national immunization programs. Expert Rev Vaccines. 2024 Dec 31;23(1):879-86. doi: 10.1080/14760584.2024.2409662
Eiden AL, Hartley L, Garbinsky D, Saande C, Russo J, Gabriel MH, Price M, Bhatti A. Adult vaccination coverage in the United States: a database analysis and literature review of improvement strategies. Hum Vaccin Immunother. 2024 Dec 31;20(1):2381283. doi: 10.1080/21645515.2024.2381283
Cappellini MD, Glassberg MB, Meyers J, Jimenez M, Nham T, Bueno L, Sieluk J, Yucel A, Alashkar F. Demographics, clinical characteristics, and real-world treatment patterns among patients with beta-thalassemia: a retrospective medical record abstraction study. Ther Adv Hematol. 2024 Dec 15;15. doi: 0.1177/20406207241298088
Pistillo A, Warkentin S, Abellan A, de Bont J, Ranger T, Perez-Crespo L, Cirach M, Perramon-Malavez A, Khalid S, Nieuwenhuijsen M, Vrijheid M, Duarte-Salles T. Residential relocation and changes in patterns of environmental exposures by health determinants among children and adolescents in Catalonia, Spain. Environ Res. 2024 Dec 15;263(Pt 2):120152. doi: 10.1016/j.envres.2024.120152
DiBenedetti D. Design considerations for in-trial interviews. Presented at the US Food and Drug Administration Patient-Focused Drug Development Virtual Workshop - Methodological and Other Challenges Related to Patient Experience Data; December 13, 2024.
Sutton Norman K, Zigler C, Brown M, Miller J, Bosworth H, Collyar D, Oakes M, Fowler V, Howard-Anderson J, Korn R, Ruffin F, Boucher H, Doemberg S, Reeve B, King H. Patient and clinician perspectives of care interactions for complicated urinary tract infections to inform implementation of patient-reported outcome measures: a qualitative descriptive study. Poster presented at the 17th Annual Conference on the Science of Dissemination and Implementation in Health; December 9, 2024. Arlington, VA.
Shadman M, Roeker L, Pinilla-Ibarz J, Srivastava B, Karve S, Krigsfeld GS, Franceschini E, Saifan C, Karanth S, Goyal RK, Rombi J, Stephens DM. Association between dose reduction and duration of therapy in patients receiving ibrutinib or acalabrutinib for chronic lymphocytic leukemia: a medical chart review study. Poster presented at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition; December 8, 2024. San Diego, California.
Kosa K, Vanegas A, Colavecchia C, Coulter J, Christopher SA, Fasano RM, Chou ST, Drachtman RA, Purdie DM, Baker CL, Meier ER. Qualitative interview study to characterize the treatment experiences of participants with sickle cell disease and assess perceptions of red blood cell transfusions. Poster presented at the American Society of Hematology (ASH) Annual Meeting & Exposition; December 8, 2024. San Diego, CA.
Benitez A, Andrews JS, Shah D, Mansfield C, Ross E, Rao S, Bussberg C, Galinksy J, Konermann-Bernhardt C, Lu M, Vass C. Caregiver preferences for dravet syndrome and lennox-gastaut syndrome treatments across the USA, UK, and Germany. Poster presented at the 2024 American Epilepsy Society (AES) Annual Meeting; December 7, 2024. Los Angeles, CA.
Krishnamurthy P, Houghton K, Lorenz N, Williams P, Currie L, Vigil CE, Ziba N, Bello F, Sieluk J, Strocchia M, Li Y, Kapp-Schwoerer S. Real-world treatment patterns and outcomes with oral azacitidine maintenance therapy in patients with acute myeloid leukemia. Poster presented at the American Society of Hematology (ASH) Annual Meeting & Exposition; December 7, 2024. San Diego, CA.
Ahn MJ, Lin SH, Yang CT, Lee JB, Neal J, Okishio K, Nishino K, Smith D, Rauter M, Jimenez M, Nagar SP, Nasirova F, Kim YJ. Treatment (Tx) patterns and clinical outcomes in unresectable (UR) stg III EGFR-mutation positive (EGFRm) NSCLC treated with chemoradiotherapy (CRT): final analysis of a global real-world (rw) study. Poster presented at the European Society for Medical Oncology (ESMO) Asia Congress 2024; December 7, 2024. Singapore, China.
Rao S, McQuay L, Forns J, MacKay R, Aquilina T, Doshi D, Abler V, Anthony MS, Layton B. Mortality in patients with Parkinson's disease psychosis using pimavanserin versus other antipsychotics. Poster presented at the 2024 Parkinson Study Group (PSG) 33rd Annual Meeting; December 5, 2024. Nashville, TN. Previously presented at the Neuroscience Education Institute (NEI) Congress 2024.
Earnshaw S, Brogan AJ, Brodtkorb TH, Davis AE. Budget impact analysis II: applications and design issues - virtual. Presented at the 2024 Virtual ISPOR Short Course Program; December 4, 2024. Previously presented at the 2015 ISPOR 20th Annual International Meeting.
Ismail Z, Meehan SR, Farovik A, Miguelez M, Kapadia S, Regnier SA, Zhang Z, Brown TM, Milien M, McIntyre RS. Assessment of patient life engagement in schizophrenia using items from the Positive and Negative Syndrome Scale. Schizophr Res. 2024 Dec;274:337-44. doi: 10.1016/j.schres.2024.10.008
Whalley D, Balp MM, Yarr S, Korver D, Sauchelli Toran S, Kohli R, Orfanos P. Psychometric evaluation of the urticaria activity score in chronic spontaneous urticaria. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S506. doi: 10.1016/j.jval.2024.10.3260
Marcano Belisario J, Lunan M, Hawe E, Thurairajah S. Machine learning and artificial intelligence for supporting systematic reviews: a systematic review of recent methodological developments and recommendations for implementation. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S636. doi: 10.1016/j.jval.2024.10.3193
Yee K, Poulos C, Bussberg C, Myers K. Patient characteristics associated with treatment preference for generalized Myasthenia Gravis (gMG): a multivariate analysis. Poster to be given at the ISPOR Europe 2024; November 17, 2025. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Suppl):S524-5.
Brockbank J, Hancock H, Khare A, Joshi P, Risson V. Cost-effectiveness of [177Lu]Lu-PSMA-617 in progressive PSMA-positive metastatic castration-resistant prostate cancer. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S121. doi: 10.1016/j.jval.2024.10.619
Barbieri M, Talbird S, Carrico J, Boccalini S, Bencina G, Bonanni P, Mellott CE, Senese F, Lang JC, Bechini A. Public health impact and return on investment of the pediatric National Immunization Program in Italy. Expert Rev Vaccines. 2024 Dec;23(1):974-85. doi: 10.1080/14760584.2024.2411425
Tavi J, Bahloul D, Kuznik A, Thomas RB, Knight C, Manga N, Sullivan SD. Economic evaluation of dupilumab versus standard of care for the treatment of adult patients with moderate-to-severe prurigo nodularis in the United States. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S104. doi: 10.1016/j.jval.2024.10.543
D'Souza V, Bhogal P, Njue A. Impact of the innovative licensing and access pathway (ILAP) designation on regulatory and health technology assessment (HTA) outcomes. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S312. doi: 10..1016/j.jval.2024.10.1623
DiBenedetti D, Neme D, Pan-Petesch B, Willemze A, Wynn T, Kragh N, Wilson A. Patient experience with efanesoctocog alfa for severe hemophilia A: results from the XTEND-1 phase 3 clinical study exit interviews. Clin Ther. 2024 Dec;46(12):1016-23. doi: 10.1016/j.clinthera.2024.09.010
Chuang CC, Pariser DM, Simpson E, Dine J, Brown M, Fehnel S, Wang Z. The atopic dermatitis control tool: adaptation and content validation for children and caregivers of children with atopic dermatitis. Dermatol Ther. 2024 Dec;14(12):3261-71. doi: 10.1007/s13555-024-01289-8
Howard K, Adelman D, Ghura S, Acaster S, Clifford S, Kelly CP, Martin SA, Meckley LM, Leffler DA. Development of the celiac disease symptom diary version 2.1© (CDSD 2.1©) patient-reported outcome measure. Qual Life Res. 2024 Dec;33(12):3275-82. doi: 10.1007/s11136-024-03799-6
Graham C, Erbe A. Hospitalization costs of common grade 3/4 adverse events associated with oncology treatments in the United States: 2024 update. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S137. doi: 10.1016/j.jval.2024.03.730
Grivas P, Barata P, Moon H, Gupta S, Hutson T, Sternberg CN, Brown JR, Dave V, Downey C, Shillington AC, Katzenstein HM, Kirker M, Hanson S, Liu FX, Morris V, Bhanegaonkar A, Sonpavde GP. Avelumab first-line maintenance for locally advanced or metastatic urothelial carcinoma: results from the Real-world US PATRIOT-II Study. Clin Genitourin Cancer. 2024 Dec;22(6):102238. doi: 10.1016/j.clgc.2024.102238
Wainberg ZA, Enzinger PC, Qin S, Yamaguchi K, Wang J, Zhou X, Gnanasakthy A, Taylor K, Yusuf A, Maher I, Jamotte A, Kang YK. Health-related quality of life with bemarituzumab plus mFOLFOX6 in patients with FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer. ESMO gastrointestinal oncology. 2024 Dec;6. doi: 10.1016/j.esmogo.2024.100095
Johannesen K, Herring WL, Chopra R, Elpers B, Dong O. Using patient-level simulation to estimate long-term survival in idiopathic pulmonary fibrosis. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S459-60. doi: 10.1016/j.jval.2024.10.2345
Neofytos D, Pagliuca A, Houghton K, Broughton E, de Figueiredo Valente MLN, Jiang L, Enoch DA, Gruener B, Herbrecht R, Lahmer T, Lortholary O, Melenotte C, De Rosa FG, Garcia-Vidal C, Jimenez M, Fernandez M, Cornely O. Effectiveness, safety, and patterns of real-world isavuconazole use in Europe (2015-2019). Infect Dis Ther. 2024 Dec;13(12):2527-43. doi: 10.1007/s40121-024-01064-4